vs
Orthofix Medical Inc.（OFIX）与Clear Secure, Inc.（YOU）财务数据对比。点击上方公司名可切换其他公司
Clear Secure, Inc.的季度营收约是Orthofix Medical Inc.的1.1倍（$240.8M vs $219.9M），Clear Secure, Inc.净利率更高（12.8% vs -1.0%，领先13.8%），Clear Secure, Inc.同比增速更快（16.7% vs 2.0%），Clear Secure, Inc.自由现金流更多（$187.4M vs $16.8M），过去两年Clear Secure, Inc.的营收复合增速更高（16.0% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Clear Secure, Inc.是美国一家科技企业，主营生物识别旅行证件核验系统，其服务已覆盖部分大型机场与体育场馆。公司成立于2003年，2009年申请破产后停运，2012年重启运营，最终于2021年成功上市。
OFIX vs YOU — 直观对比
营收规模更大
YOU
是对方的1.1倍
$219.9M
营收增速更快
YOU
高出14.7%
2.0%
净利率更高
YOU
高出13.8%
-1.0%
自由现金流更多
YOU
多$170.6M
$16.8M
两年增速更快
YOU
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $240.8M |
| 净利润 | $-2.2M | $30.8M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 22.4% |
| 净利率 | -1.0% | 12.8% |
| 营收同比 | 2.0% | 16.7% |
| 净利润同比 | 92.4% | -70.2% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXYOU
| Q4 25 | $219.9M | $240.8M | ||
| Q3 25 | $205.6M | $229.2M | ||
| Q2 25 | $203.1M | $219.5M | ||
| Q1 25 | $193.6M | $211.4M | ||
| Q4 24 | $215.7M | $206.3M | ||
| Q3 24 | $196.6M | $198.4M | ||
| Q2 24 | $198.6M | $186.7M | ||
| Q1 24 | $188.6M | $179.0M |
净利润OFIXYOU
| Q4 25 | $-2.2M | $30.8M | ||
| Q3 25 | $-22.8M | $28.3M | ||
| Q2 25 | $-14.1M | $24.7M | ||
| Q1 25 | $-53.1M | $25.4M | ||
| Q4 24 | $-29.1M | $103.3M | ||
| Q3 24 | $-27.4M | $23.5M | ||
| Q2 24 | $-33.4M | $24.1M | ||
| Q1 24 | $-36.0M | $18.8M |
毛利率OFIXYOU
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXYOU
| Q4 25 | 0.2% | 22.4% | ||
| Q3 25 | -8.3% | 23.0% | ||
| Q2 25 | -7.9% | 19.4% | ||
| Q1 25 | -25.2% | 17.7% | ||
| Q4 24 | -5.3% | 16.5% | ||
| Q3 24 | -9.6% | 17.7% | ||
| Q2 24 | -12.5% | 16.2% | ||
| Q1 24 | -15.6% | 13.2% |
净利率OFIXYOU
| Q4 25 | -1.0% | 12.8% | ||
| Q3 25 | -11.1% | 12.3% | ||
| Q2 25 | -6.9% | 11.3% | ||
| Q1 25 | -27.4% | 12.0% | ||
| Q4 24 | -13.5% | 50.1% | ||
| Q3 24 | -13.9% | 11.8% | ||
| Q2 24 | -16.8% | 12.9% | ||
| Q1 24 | -19.1% | 10.5% |
每股收益（稀释后）OFIXYOU
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $85.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $177.7M |
| 总资产 | $850.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXYOU
| Q4 25 | $82.0M | $85.7M | ||
| Q3 25 | $62.9M | $75.8M | ||
| Q2 25 | $65.6M | $89.3M | ||
| Q1 25 | $58.0M | $87.6M | ||
| Q4 24 | $83.2M | $66.9M | ||
| Q3 24 | $30.1M | $32.9M | ||
| Q2 24 | $26.4M | $39.1M | ||
| Q1 24 | $27.0M | $64.1M |
总债务OFIXYOU
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXYOU
| Q4 25 | $450.0M | $177.7M | ||
| Q3 25 | $442.5M | $148.6M | ||
| Q2 25 | $458.3M | $121.3M | ||
| Q1 25 | $458.3M | $116.7M | ||
| Q4 24 | $503.1M | $198.4M | ||
| Q3 24 | $525.9M | $129.0M | ||
| Q2 24 | $546.0M | $153.5M | ||
| Q1 24 | $570.3M | $165.9M |
总资产OFIXYOU
| Q4 25 | $850.6M | $1.3B | ||
| Q3 25 | $832.6M | $1.1B | ||
| Q2 25 | $837.2M | $1.2B | ||
| Q1 25 | $823.1M | $1.1B | ||
| Q4 24 | $893.3M | $1.2B | ||
| Q3 24 | $867.9M | $858.6M | ||
| Q2 24 | $882.0M | $982.4M | ||
| Q1 24 | $906.0M | $1.0B |
负债/权益比OFIXYOU
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $198.4M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $187.4M |
| 自由现金流率自由现金流/营收 | 7.6% | 77.8% |
| 资本支出强度资本支出/营收 | 4.9% | 4.6% |
| 现金转化率经营现金流/净利润 | — | 6.45× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $343.1M |
8季度趋势，按日历期对齐
经营现金流OFIXYOU
| Q4 25 | $27.7M | $198.4M | ||
| Q3 25 | $12.4M | $-47.3M | ||
| Q2 25 | $11.6M | $123.0M | ||
| Q1 25 | $-18.4M | $98.3M | ||
| Q4 24 | $23.7M | $136.6M | ||
| Q3 24 | $11.7M | $-35.9M | ||
| Q2 24 | $9.0M | $114.6M | ||
| Q1 24 | $-18.6M | $80.3M |
自由现金流OFIXYOU
| Q4 25 | $16.8M | $187.4M | ||
| Q3 25 | $2.5M | $-53.5M | ||
| Q2 25 | $4.5M | $117.9M | ||
| Q1 25 | $-25.1M | $91.3M | ||
| Q4 24 | $15.2M | $133.9M | ||
| Q3 24 | $6.3M | $-37.9M | ||
| Q2 24 | $-360.0K | $110.1M | ||
| Q1 24 | $-29.1M | $77.6M |
自由现金流率OFIXYOU
| Q4 25 | 7.6% | 77.8% | ||
| Q3 25 | 1.2% | -23.3% | ||
| Q2 25 | 2.2% | 53.7% | ||
| Q1 25 | -13.0% | 43.2% | ||
| Q4 24 | 7.0% | 64.9% | ||
| Q3 24 | 3.2% | -19.1% | ||
| Q2 24 | -0.2% | 59.0% | ||
| Q1 24 | -15.4% | 43.3% |
资本支出强度OFIXYOU
| Q4 25 | 4.9% | 4.6% | ||
| Q3 25 | 4.8% | 2.7% | ||
| Q2 25 | 3.5% | 2.3% | ||
| Q1 25 | 3.5% | 3.4% | ||
| Q4 24 | 4.0% | 1.3% | ||
| Q3 24 | 2.7% | 1.0% | ||
| Q2 24 | 4.7% | 2.4% | ||
| Q1 24 | 5.6% | 1.6% |
现金转化率OFIXYOU
| Q4 25 | — | 6.45× | ||
| Q3 25 | — | -1.67× | ||
| Q2 25 | — | 4.97× | ||
| Q1 25 | — | 3.87× | ||
| Q4 24 | — | 1.32× | ||
| Q3 24 | — | -1.53× | ||
| Q2 24 | — | 4.75× | ||
| Q1 24 | — | 4.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
YOU
暂无分部数据
